Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

86 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Alectinib for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status (Lung Oncology Group in Kyushu 1401).
Iwama E, Goto Y, Murakami H, Harada T, Tsumura S, Sakashita H, Mori Y, Nakagaki N, Fujita Y, Seike M, Bessho A, Ono M, Okazaki A, Akamatsu H, Morinaga R, Ushijima S, Shimose T, Tokunaga S, Hamada A, Yamamoto N, Nakanishi Y, Sugio K, Okamoto I. Iwama E, et al. Among authors: bessho a. J Thorac Oncol. 2017 Jul;12(7):1161-1166. doi: 10.1016/j.jtho.2017.02.012. Epub 2017 Feb 24. J Thorac Oncol. 2017. PMID: 28238961 Free article. Clinical Trial.
Interstitial lung disease in Japanese patients with non-small cell lung cancer receiving gefitinib: an analysis of risk factors and treatment outcomes in Okayama Lung Cancer Study Group.
Hotta K, Kiura K, Tabata M, Harita S, Gemba K, Yonei T, Bessho A, Maeda T, Moritaka T, Shibayama T, Matsuo K, Kato K, Kanehiro A, Tanimoto Y, Matsuo K, Ueoka H, Tanimoto M. Hotta K, et al. Among authors: bessho a. Cancer J. 2005 Sep-Oct;11(5):417-24. doi: 10.1097/00130404-200509000-00010. Cancer J. 2005. PMID: 16259873
Triple combination chemotherapy with cisplatin, docetaxel, and irinotecan for advanced non-small cell lung cancer: a phase I/II trial.
Kiura K, Takigawa N, Segawa Y, Tabata M, Shibayama T, Gemba K, Bessho A, Fujimoto N, Takata I, Hotta K, Fujiwara K, Tokuda Y, Kuyama S, Shinkai T, Ueoka H, Tanimoto M; Okayama Lung Cancer Study Group. Kiura K, et al. Among authors: bessho a. J Thorac Oncol. 2007 Jan;2(1):44-50. doi: 10.1097/JTO.0b013e31802bafe2. J Thorac Oncol. 2007. PMID: 17410009 Free article. Clinical Trial.
A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705.
Yoshioka H, Hotta K, Kiura K, Takigawa N, Hayashi H, Harita S, Kuyama S, Segawa Y, Kamei H, Umemura S, Bessho A, Tabata M, Tanimoto M; Okayama Lung Cancer Study Group. Yoshioka H, et al. Among authors: bessho a. J Thorac Oncol. 2010 Jan;5(1):99-104. doi: 10.1097/JTO.0b013e3181c20063. J Thorac Oncol. 2010. PMID: 19898258 Free article. Clinical Trial.
Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese Patients with non-small cell lung cancer: the Okayama Lung Cancer Study Group experience.
Hotta K, Kiura K, Takigawa N, Yoshioka H, Harita S, Kuyama S, Yonei T, Fujiwara K, Maeda T, Aoe K, Ueoka H, Kamei H, Umemura S, Moritaka T, Segawa Y, Kawai H, Bessho A, Kato K, Tabata M, Tanimoto M. Hotta K, et al. Among authors: bessho a. J Thorac Oncol. 2010 Feb;5(2):179-84. doi: 10.1097/JTO.0b013e3181ca12e0. J Thorac Oncol. 2010. PMID: 20101144 Free article.
86 results